1. Document de presse | 2021.03.23

   SARS-CoV-2 variants of interest can infect mice: host range extended

   SARS-CoV-2, the virus responsible for COVID-19, is capable of infecting some species, while others are naturally resistant to it. This determines the "host range" of the virus. The SARS-CoV-2 host range includes humans, non-human primates, hamsters, mink and cats. Since the start of the pandemic, mice and rats had proven to be resistant to SARS-CoV-2, because their ACE2 receptor, which allows the...

2. News | 2023.12.11

   Toscana virus causes unexplained encephalitis

   A team from the Institut Pasteur in Paris, in collaboration with researchers in Spain, has identified Toscana virus in samples taken from patients in southern Spain. This virus is responsible for cases of encephalitis that have never been fully explained. The presence of this virus in the samples challenges the assumption that it was rare in the Mediterranean region. Thanks to this discovery,...

3. News | 2022.07.22

   Improving bacterial strain classification for more effective surveillance

   Genomic research on bacterial strains can provide the tools to develop a new classification system, leading to improved epidemiological surveillance, especially for antibiotic-resistant strains.

4. News | 2024.11.04

   A novel method for producing DNA-based therapies

   Scientists have combined enzyme and chemical techniques to develop an innovative method for producing synthetic DNA molecules. This novel approach opens up many new possibilities, especially for the production of large molecules that can be used for future therapies.

5. News | 2023.05.23

   Creation of an European Biocluster for Emerging Infectious Diseases

   The project "Infectious Diseases Cluster" (IDCluster) has been selected for the Healthcare Innovation 2030 plan. This strategy aims to strengthen biomedical research in France. Coordinated by Lyonbiopôle and supported by the Auvergne-Rhône-Alpes region, this European-scale cluster aims to accelerate progress in the field of emerging diseases, by working with the Institut Pasteur among others.

6. News | 2020.06.18

   Phylogenetic analysis of SARS-CoV-2: strengths, limitations and over-interpretations

   The Institut Pasteur's bioinformatics research teams have been closely involved in the response to COVID-19, working to analyze the sequencing data produced worldwide. On January 29, 2020, the Institut Pasteur, which is responsible for monitoring respiratory viruses in France, was the first in Europe to sequence the whole genome of the coronavirus known as SARS-CoV-2. Since then, it has sequenced...

7. Document de presse | 2020.10.16

   Team of international scientists identify common vulnerabilities across SARS-CoV-2, SARS-CoV-1 and MERS coronaviruses

   Driven by Molecular Insights, Massive Analysis of Medical Records from ~740,000 SARS-CoV-2 Patients Reveal Treatment Regimens for Current, and Potential Future, Viral Pandemics. Published on October 15, 2020, in Science. In a study published online in Science, an international team of almost 200 researchers from 14 leading institutions in six countries, including France with the...

8. News | 2021.02.15

   Discovery of messenger RNA in 1961

   Since the beginning of the COVID-19 pandemic, words that just a year ago would have been the preserve of scientists have entered everyday language. One example is PCR, used for diagnostic tests. Another term that was once unfamiliar and is now on everyone's lips is messenger RNA, the miraculous molecule that has led to vaccines being administered to the general population less than a year after...

9. News | 2023.06.16

   Strategic Plan: research advances in 2022

   Five major themes were at the core of 2022 research advances: emerging infectious diseases, antimicrobial resistance, brain connectivity and neurodegenerative diseases, cancer, vaccinology and immunotherapy. They have honored Institut Pasteur's 2019-2023 strategic plan.

10. News | 2023.09.05

    HIV-AIDS: broadly neutralizing antibodies, stars of the lab

    Highly promising, broadly neutralizing antibodies can react with the vast majority of HIV particles to cause their destruction by the body. However, the latter would have to be able to produce equally effective antibodies...

Pages